10-Year Follow-Up: Pembrolizumab Outshines Ipilimumab in Advanced Melanoma
Long-term study shows pembrolizumab's superior efficacy over ipilimumab for advanced melanoma patients.
Head & Neck Cancer
8 articles
Durvalumab vs Cetuximab: No Advantage in Head and Neck Cancer Trial
Study finds durvalumab with radiotherapy no better than cetuximab for cisplatin-ineligible head and neck cancer
Breakthrough Combo Therapy Extends Survival in Aggressive Thyroid Cancer
Novel combination therapy shows promise for anaplastic thyroid carcinoma, significantly improving survival.
Once-Every-3-Weeks Cisplatin Triumphs in Long-Term Head and Neck Cancer Study
Long-term analysis shows superior locoregional control with high-dose cisplatin in head and neck cancer.
Cisplatin Schedules in Head and Neck Cancer: Weekly vs Bolus Regimens Show Similar Survival Outcomes
Network meta-analysis finds no significant difference in survival between weekly and bolus cisplatin for head and neck cancer.
Genetic Variants Linked to Higher Mortality Risk in Cancer Chemotherapy
Meta-analysis reveals DPYD gene variants significantly increase death risk in fluoropyrimidine chemotherapy.
Weekly Cisplatin: A Kidney-Friendly Approach for Head and Neck Cancer Treatment
Study finds weekly cisplatin reduces kidney injury risk without compromising survival in head/neck cancer.
Immunotherapy Breakthrough: Toripalimab Boosts Survival in Nasopharyngeal Cancer
Toripalimab plus chemotherapy significantly improves survival in recurrent/metastatic nasopharyngeal carcinoma.
L-Glutamine: A Safe Supplement for Head and Neck Cancer Patients Undergoing Chemoradiotherapy
Study finds L-glutamine supplementation does not negatively impact survival in head and neck cancer patients